Croma-Pharma Completed the Decentralized Procedure for Its Botulinum Toxin to Treat Glabellar (frown) Lines
Croma-Pharma (Croma), today announced that the decentralized procedure for its botulinum toxin to gain market authorization in Europe has been accomplished. This important step is the basis to complete
Source: finanznachrichten.de